B. E. Evans

发表

J. D. Griffiths, B. E. Evans, 1976 .

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.

B. E. Evans, D. Veber, K. Rittle, 1988, Journal of medicinal chemistry.

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.

B. E. Evans, D. Veber, K. Rittle, 1988, Journal of medicinal chemistry.

Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.

B. E. Evans, D. Veber, K. Rittle, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Catalysis of the covalent hydration of pteridine by adenosine aminohydrolase.

B. E. Evans, R. Wolfenden, 1973, Biochemistry.

Synthesis and resolution of 3-amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones

B. E. Evans, D. Veber, K. Rittle, 1987 .

Progress in the development of oxytocin antagonists for use in preterm labor.

B. E. Evans, M. Bock, D. Reiss, 1995, Advances in experimental medicine and biology.

An expedient synthesis of 3-amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one

B. E. Evans, D. Veber, K. Rittle, 1987 .

Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.

B. E. Evans, K. Rittle, M. Bock, 1989, Journal of medicinal chemistry.

MK‐329: A non‐peptide cholecystokinin a antagonist

B. E. Evans, 1993 .

Multipurpose receptor ligands: β-carboline cholecystokinin antagonists

B. E. Evans, K. Rittle, R. Freidinger, 1993 .

Design of cholecystokinin peptidomimetics

B. E. Evans, D. Veber, K. Rittle, 1992 .

Development and pharmacological assessment of novel peptide and nonpeptide oxytocin antagonists

B. E. Evans, D. Veber, M. Bock, 1993, Regulatory Peptides.

L‐368,899, a potent orally active oxytocin antagonist for potential use in preterm labor

B. E. Evans, M. Kaufman, D. Veber, 1993 .

1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido) bicyclo(2.2.1)heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl) piperazine (L-368,899): An Orally Bioavailable, Non-Peptide Oxytocin Antagonist with Potential Utility for Managing Preterm Labor.

B. E. Evans, M. Bock, R. Freidinger, 1994 .

1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.

B. E. Evans, M. Bock, P. Anderson, 1994, Journal of medicinal chemistry.

A stereocontrolled synthesis of hydroxyethylene dipeptide isosteres using novel, chiral aminoalkyl epoxides and .gamma.-(aminoalkyl)-.gamma.-lactones

B. E. Evans, D. Veber, K. Rittle, 1985 .

A Stereocontrolled Synthesis of Hydroxyethylene Dipeptide Isosteres Using Novel, Chiral Aminoalkyl Epoxides and γ-(Aminoalkyl) γ-Lactones.

B. E. Evans, D. Veber, K. Rittle, 1986 .

Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.

B. E. Evans, M A Jacobson, M. Bock, 1999, Bioorganic & medicinal chemistry letters.

Covalent addition of ammonia to pteridine: the 3,4-monoadduct

B. E. Evans, 1974 .

Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility.

B. E. Evans, D. Veber, K. Rittle, 1986, Journal of medicinal chemistry.

Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.

B. E. Evans, D. Veber, K. Rittle, 1988, Journal of medicinal chemistry.

Transannular reactions of dibenzo[a,d]cycloalkenes. 2. Synthesis of bridgehead substituted dibenzo[a,d]cycloalkenimines by a regiospecific transannular amine to olefin addition

B. E. Evans, K. Rittle, P. Anderson, 1979 .

Thermolysis and transannular reactions of 8,8-dichloro-2,3:5,6-dibenzobicyclo[5.1.0]octane derivatives

B. E. Evans, P. Anderson, M. Christy, 1978 .

Renin inhibitors containing hydrophilic groups. Tetrapeptides with enhanced aqueous solubility and nanomolar potency.

B. E. Evans, K. Rittle, M. Bock, 1988, Journal of medicinal chemistry.

A synthesis of statine utilizing an oxidative route to chiral .alpha.-amino aldehydes

B. E. Evans, K. Rittle, G. Ponticello, 1982 .

Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.

B. E. Evans, D. Veber, K. Rittle, 1987, Journal of medicinal chemistry.

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 1. Structural modification of 5-substituted 3,5-dihydroxypentanoic acids and their lactone derivatives.

B. E. Evans, W. F. Hoffman, A. Deana, 1985, Journal of Medicinal Chemistry.

Cycloalkylpiperazines as HIV-1 protease inhibitors: enhanced oral absorption

B. E. Evans, P. Anderson, Jiunn H. Lin, 1995 .

Transannular reactions of dibenzo[a,d]cycloalkenes. 3. Nature of the amine to olefin ring closure

B. E. Evans, P. Anderson, 1981 .

Reactions of Sodiurn Borohydride in Acidic Media; IV. Reduction of Diarylmethanols and Triarylmethanols in Trifluoroacetic Acid1-3

B. E. Evans, G. Gribble, R. Leese, 1977 .

A new amine resolution method and its application to 3-aminobenzodiazepines

B. E. Evans, D. Veber, K. Rittle, 1987 .

A New Amine Resolution Method and Its Application to 3‐Aminobenzodiazepines.

B. E. Evans, D. Veber, K. Rittle, 1987 .

Photochemical addition of alcohols to an amidine C==N bond

B. E. Evans, E. Taylor, Y. Maki, 1969 .

Orally active, nonpeptide oxytocin antagonists.

B. E. Evans, D. Veber, K. Rittle, 1992, Journal of medicinal chemistry.

Nanomolar-affinity, non-peptide oxytocin receptor antagonists.

B. E. Evans, K. Rittle, M. Bock, 1993, Journal of medicinal chemistry.

Identification of an orally active, nonpeptidyl oxytocin antagonist.

B. E. Evans, D. Veber, R. Freidinger, 1993, The Journal of pharmacology and experimental therapeutics.

Complete amino acid analysis of peptides and proteins after hydrolysis by a mixture of sepharose-bound peptidases.

B. E. Evans, D. F. Elliott, C. McMartin, 1972, The Biochemical journal.

Development of 1,4-benzodiazepine cholecystokinin type B antagonists.

B. E. Evans, K. Rittle, M. Bock, 1993, Journal of medicinal chemistry.

Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines.

B. E. Evans, K. Rittle, M. Bock, 1988, Journal of medicinal chemistry.

Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.

B. E. Evans, D. Veber, K. Rittle, 1990, Journal of medicinal chemistry.

Synthesis and Resolution of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones.

B. E. Evans, D. Veber, K. Rittle, 1988 .

Transannular reactions of dibenzo[a,d]cycloalkenes. 1. Synthesis of dibenzo[a,d]cycloocten-6,12-imines and dibenzo[a,d]cyclohepten-5,10-imines

B. E. Evans, P. Anderson, M. Christy, 1979 .

Novel oxytocin antagonists

B. E. Evans, D. Veber, M. Bock, 1993 .

Orally active, non-peptide oxytocin antagonists

B. E. Evans, D. Veber, M. Bock, 1994 .

[A potential transition state analog for adenosine deaminase].

B. E. Evans, R. Wolfenden, B. Evans, 1970, Journal of the American Chemical Society.